Sitting Could Be Shrinking Your Brain (And Exercise May Not Help)
The research counters the idea that periods of sitting can be balanced out by periods of being active, at least when it comes to brain health in people aged 50 or above.
The study researchers, from Vanderbilt University, the University of Pittsburgh, and Seoul National University, think that too much sitting or lying down (known as sedentary behavior) can impact the brain and increase the risk of different types of dementia later in life, including Alzheimer's disease.
"Reducing your risk for Alzheimer's disease is not just about working out once a day," says neurologist Marissa Gogniat, from the University of Pittsburgh.
"Minimizing the time spent sitting, even if you do exercise daily, reduces the likelihood of developing Alzheimer's disease."
The researchers recruited 404 volunteers, tracking their activity levels with wearables over the course of a week. Then, over the next seven years, cognitive tests and brain scans were used to assess their brain health.
Even though 87 percent of the volunteers were meeting the recommended weekly guidelines of at least 150 minutes of moderate-intensity exercise, those who sat more overall showed worse cognition.
They also showed more signs of neurodegeneration – including a faster thinning of the hippocampus, a part of the brain crucial to memory function and one of the first areas to show damage from Alzheimer's.
The association wasn't huge, and doesn't prove direct cause and effect, but it was noticeable: spending more time sitting seems to age the brain faster, and reducing that amount of time, rather than just exercising more, appears to be the best antidote.
Stronger associations were found in those already at a higher genetic risk of Alzheimer's, the data shows.
"This research highlights the importance of reducing sitting time, particularly among aging adults at increased genetic risk for Alzheimer's disease," says neurologist Angela Jefferson, from the Vanderbilt University Medical Center.
"It is critical to our brain health to take breaks from sitting throughout the day and move around to increase our active time."
Of course, these findings aren't a reason to give up more vigorous exercise. We know that being active does wonders for our physical and mental health, and even small amounts of exercise can keep the brain sharp.
What's most important here is that extra hours sitting down were linked to certain kinds of wear and tear in the brain. This isn't the first time that sedentary behavior has been linked with dementia and Alzheimer's, but it's another important and comprehensive set of data that researchers and health professionals can draw on.
"It is critical to study lifestyle choices and the impact they have on brain health as we age," says Jefferson.
The research has been published in Alzheimer's & Dementia.
Want to Live to 100? These Four Habits Might Help Get You There.
Common Energy Drink Additive Could Be Fueling Growth in Leukemia
Yellow Fever Resurgence Could Make COVID Look 'Pale' by Comparison
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
5 hours ago
- Business Upturn
Roche receives CE Mark for minimally invasive blood test to help rule out Alzheimer's disease
Elecsys pTau181 is the first In Vitro Diagnostic Regulation (IVDR) certified test to rule out Alzheimer's associated amyloid pathology. The minimally invasive, blood-based test can serve as a rule out for Alzheimer's pathology, reducing the need for confirmatory testing with a negative result. Data from clinical study supports use in primary care for people with varying signs of cognitive decline. Basel, 23 July 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today it has received CE Mark for its Elecsys® pTau181 test to measure phosphorylated Tau (pTau) 181 protein which is an indicator of amyloid pathology, a hallmark of Alzheimer's disease. The test, which has been developed in collaboration with Eli Lilly and Company, can be used by clinicians in conjunction with other clinical information to rule out Alzheimer's disease as the cause of cognitive decline. This could avoid the need for further confirmatory investigation for patients testing negative. 'The burden of Alzheimer's disease on society and healthcare systems is increasing as the world's population ages,' said Matt Sause, CEO of Roche Diagnostics. 'With Elecsys pTau181, doctors can give patients and their caregivers the clarity they need when establishing the cause of cognitive decline. By enabling an earlier and less invasive diagnosis, this test has the potential to improve patient outcomes and decrease costs for healthcare systems worldwide.' Barriers to early and accurate diagnosis of Alzheimer's disease exist across the world. Up to 75% of people living with symptoms are not diagnosed, and those who have received a diagnosis waited nearly three years on average after symptom onset.1 The identification of amyloid pathology is critical for Alzheimer's diagnosis and treatment. Current methods to confirm amyloid pathology – including positron emission tomography (PET) and cerebrospinal fluid (CSF) assessment – can be expensive, difficult to access and invasive. With a negative Elecsys pTau181 blood test, people can avoid further unnecessary investigations for Alzheimer's using CSF or PET and can identify the care pathway that is right for them. Clinical study results support that the test can be implemented effectively across care settings, including primary care, where most patients first seek help for cognitive concerns. Those with positive results are then able to undergo further testing, supporting earlier identification of Alzheimer's pathology. This is key to accessing new treatments that are most effective when used early in the disease progression, enabling patients to make informed decisions about their future care. Clinical data support the Elecsys pTau181 test for varying signs of cognitive decline The CE Mark for the Elecsys pTau181 blood test was based on data from a prospective, multicentre study, which included 787 patients across the US, Europe and Australia. The study showed the test was able to rule out Alzheimer's disease with a high negative predictive value (NPV) of 93.8% based on a 22.5% prevalence of amyloid positivity according to positron emission tomography (PET) scans, with 83.6% sensitivity. The rule out performance of the test was only minimally impacted by the patients' age, gender, body mass index or impaired kidney function. This global, prospectively-collected, diagnostic registrational clinical study was the first of its kind in the industry to investigate the test's clinical performance in a diverse patient population, aged 55-80 years old that reflects as closely as possible the patients who could benefit from the test. It involved a subset of patients from a wider study looking at a highly diverse set of patients with broad inclusion criteria, to ensure the test could be used effectively across different geographies and ethnicities. Elecsys pTau217 blood test Roche is also developing the Elecsys pTau217 blood test, an in-vitro diagnostic immunoassay for the quantitative determination of the protein Phospho-Tau (217P) in human plasma for use as an aid in identifying amyloid pathology. Recent data presented on Elecsys pTau217 showed that it was able to accurately detect amyloid pathology and was more stable than a pTau217/Aβ42 ratio in blood and plasma samples at room and refrigerator temperatures. Together with the high throughput and full automation of the assay, these data support the potential of Elecsys pTau217 as an accurate standalone test that could be scaled up for broad implementation in routine clinical practice worldwide across Roche's unmatched installed base. About Roche in Alzheimer's With more than two decades of scientific research in Alzheimer's disease, Roche is working towards a day when we can detect and treat the disease early, in order to stop or even prevent its progression to preserve what makes people who they are. Today, the company's Alzheimer's disease portfolio spans investigational medicines for different targets, types and stages of the disease, including trontinemab. On the diagnostics side, it also includes approved and investigational tools, including digital, blood-based tests and CSF assays, aiming to more effectively detect, diagnose and monitor the disease. Yet the global challenges of Alzheimer's disease go well beyond the capabilities of science, and making a meaningful impact requires collaboration both within the Alzheimer's community and outside of healthcare. Roche will continue to work together with numerous partners with the hope to transform millions of lives. About Roche Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. For over 125 years, sustainability has been an integral part of Roche's business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit . All trademarks used or mentioned in this release are protected by law. References [1] Alzheimer's Disease International. World Alzheimer Report 2022 [Internet; cited April 2025]. Available from: . Last accessed: April 2025 Roche Global Media Relations Phone: +41 61 688 8888 / e-mail: [email protected] Hans Trees, PhD Phone: +41 79 407 72 58 Sileia Urech Phone: +41 79 935 81 48 Nathalie Altermatt Phone: +41 79 771 05 25 Lorena Corfas Phone: +41 79 568 24 95 Simon Goldsborough Phone: +44 797 32 72 915 Karsten Kleine Phone: +41 79 461 86 83 Kirti Pandey Phone: +49 172 6367262 Yvette Petillon Phone: +41 79 961 92 50 Dr Rebekka Schnell Phone: +41 79 205 27 03 Roche Investor Relations Investor Relations North America Loren KalmPhone: +1 650 225 3217 e-mail: [email protected] Attachment Media Investor Release Elecsys pTau181 CE Mark English Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Health Line
13 hours ago
- Health Line
How to Get a Parkinson's Diagnosis
Key takeaways Parkinson's disease is diagnosed through a clinical evaluation, where doctors review medical history, symptoms, and eliminate other potential causes, as there isn't a single definitive test. Key signs of Parkinson's include slow movement, muscle rigidity, tremors, and balance issues, but early non-motor symptoms like sleep disturbances, mood changes, and autonomic dysfunction can appear years before diagnosis. Although blood tests, spinal fluid tests, and imaging can't diagnose Parkinson's, they do help rule out similar conditions; genetic testing and response to levodopa may offer supportive evidence. Parkinson's disease is a movement disorder caused by the loss of dopamine-producing cells in a part of your brain called the substantia nigra. Parkinson's is the second most common neurodegenerative disorder behind Alzheimer's disease. It affects nearly a million people in the United States. No single test can definitively confirm that you have Parkinson's disease. Doctors make a Parkinson's diagnosis clinically, meaning they use their judgment to make the diagnosis after: reviewing your medical history examining your symptoms ruling out conditions that cause similar symptoms Read on to learn more about the symptoms that can be early signs of Parkinson's disease and how a Parkinson's diagnosis is made. What are the signs and symptoms of Parkinson's? Parkinson's disease is a progressive condition, and symptoms tend to get worse over time. The rate of progression varies between people. At first, symptoms tend to be mild enough that they likely won't interfere with your daily life. But people who regularly spend time with you may notice changes in your gait, posture, or facial expressions. Parkinson's symptoms usually start on one side of your body before progressing to both sides. The four primary symptoms of Parkinson's include: slowness of movement (bradykinesia) muscle rigidity tremor postural instability Symptoms vary between individuals. For example, about 25 percent of people with Parkinson's don't experience a tremor. Even if you don't exhibit all the symptoms, you need to have slowness of movement for your doctor to make the diagnosis. Slowness of movement might manifest in numerous ways, such as: reduced blinking rate lack of facial expression trouble initiating movements like standing from a seated position Along with these four primary signs, other early symptoms of Parkinson's can include: soft voice or voice changes small handwriting shuffling steps stooped posture balance problems Parkinson's also commonly causes non-motor symptoms in the early stages. There's substantial evidence that these non-motor symptoms can appear several years before diagnosis, including: dysfunction of autonomic nervous system general body pain fatigue restless sleep mental changes constipation loss of bladder control erectile dysfunction depression anxiety What's next? If you begin to notice these symptoms gradually progressing, developing a treatment plan early is crucial. If you notice any changes in your movement that you believe could be signs of Parkinson's, visit a primary care physician. If they suspect that you may have Parkinson's, they'll refer you to a neurologist who specializes in movement disorders. What are the diagnostic criteria for Parkinson's? Doctors diagnose Parkinson's clinically based on your symptoms and medical history. No individual test can be used to diagnose Parkinson's. Many other neurogenerative conditions can lead to similar symptoms, so your doctor may use a blood test, brain scans, or other tests to rule out other conditions. Medical history and physical exam The process of diagnosing Parkinson's usually begins with the neurologist evaluating your medical history and performing a physical exam. For a formal diagnosis to be made, you need to have a general slowness of movement with either a resting tremor or rigidity. During the physical exam, your doctor will have you perform a series of tests to monitor your movement. An example of a test they might use is a finger tap, where they measure how many times you can tap your finger in 10 to 15 seconds. They will also look for signs that you may have another condition. A group of movement disorders collectively called parkinsonisms can produce symptoms that are indistinguishable from those of Parkinson's but are not the same. Usually, additional tests are needed to rule out these conditions as well. Blood tests and spinal fluid tests A blood test or spinal fluid test can't be used to diagnose Parkinson's. But they can be used to search for certain proteins that indicate you may have another neurodegenerative condition with similar symptoms. The presence of elevated levels of a nerve protein called neurofilament light chain protein may indicate that you have another movement disorder, such as: multiple system atrophy progressive supranuclear palsy corticobasal degeneration Genetic testing Most people who have Parkinson's don't have a family history of the disease. But there does seem to be a genetic link in about 10 percent of cases. Researchers have found that mutations in some genes seem to be linked to the development of Parkinson's, such as: PINK1 PARK7 SNCA LRRK2 If you have a family history of Parkinson's, genetic testing may provide supportive evidence for a Parkinson's diagnosis. Imaging Your doctor may refer you for imaging tests to help rule out conditions similar to Parkinson's. The brain of somebody with Parkinson's looks the same as the brain of a person without the disease when examined with most imaging tests, such as magnetic resonance imaging (MRI). But an MRI can be used to rule out conditions such as normal pressure hydrocephalus or a subcortical stroke. An imaging technique called a DaTscan can be used to identify the loss of dopamine in your brain. This may help medical professionals differentiate between essential tremor and Parkinson's. Response to medication Although it's not used as a primary diagnostic method, if the medication levodopa helps manage your symptoms, it provides supportive evidence that you have Parkinson's. Usually, other movement disorders that cause similar symptoms don't respond to Levodopa or don't respond for long. How can I try to get an early diagnosis? By the time Parkinson's causes noticeable motor symptoms, usually about 50 percent of the cells that produce dopamine in your substantia nigra have already died off. Non-motor symptoms, such as constipation, loss of smell, or restless sleep, often appear before motor symptoms. There's still debate among medical professionals on how long non-motor symptoms may appear before an individual has noticeable changes in their movement. It's thought that they could appear years to decades beforehand. But a formal Parkinson's diagnosis requires the symptom slowness of movement. In the time before this symptom appears, your doctor can't make a Parkinson's diagnosis, but they may alert you that you're at a high risk of developing Parkinson's in the future if these or other symptoms appear at any point. What are my next steps? If your doctor doesn't diagnose Parkinson's, they can help you find out what the best next step is depending on what condition they suspect. In some cases, treatment may be as simple as changing the dosage of a medication that may be leading to Parkinson's-like symptoms. Receiving a Parkinson's diagnosis can be overwhelming. If your diagnosis is confirmed, contact a movement disorder specialist as soon as possible. A specialist can help you develop a strategy to delay the onset of more severe disease and manage symptoms you're already experiencing. Make lifestyle changes Making lifestyle changes may also help you manage your symptoms. Many people find their symptoms flare up during periods of stress. Adding relaxing activities to your daily routine like yoga or meditation may help you minimize flare-ups. Some early research has found that exercise may help slow the progression of Parkinson's by stimulating the production of a molecule called brain-derived neurotrophic factor in your brain. Many gyms now offer boxing classes for people with Parkinson's to help them manage their symptoms. Other forms of exercise are thought to be effective as well, but boxing has become a popular option. Participate in clinical trials Joining a clinical trial can help contribute to Parkinson's research and may even help you with your symptoms by giving you access to state-of-the-art treatment. You can find clinical trials in your area by searching the NIH database. The Michael J. Fox Foundation also offers a clinical trial matching tool on their website. What's the outlook for a Parkinson's diagnosis? No single test can provide enough information for a doctor to diagnose Parkinson's. A doctor can diagnose Parkinson's clinically by examining your symptoms and medical history. They will likely also recommend other tests, such as imaging or blood tests, to rule out conditions that can cause similar symptoms. Parkinson's gets worse over time, but its progression varies in different people. Many people are able to manage their symptoms for many years before experiencing debilitating symptoms.
New York Post
13 hours ago
- New York Post
Expert outlines grim reality of MRI's dangers after man with 20-pound chain dies in machine mishap: ‘Snap his neck'
The Long Island man killed in a freak MRI accident stood no chance against the machine's magnetic field that pulled him in with enough force to 'snap his neck,' according to an expert in the field. A 20-pound chain that Kevin McAllister was wearing around his neck would have been yanked into the machine at Nassau Open MRI with 'hundreds of pounds' of force, Dr. Emanuel Kanal told the Post on Tuesday. 'Even if he was standing there holding the chain in his hands, the strongest weightlifter would not be able to prevent this kind of an accident from happening,' said Kanal, director of Magnetic Resonance Service at the University of Pittsburgh Medical Center. 3 Keith McAllister, 61, suffered multiple heart attacks after he was sucked into an MRI machine by his 20-pound metal chain. Facebook/Karim McAllister 'The problem is it's not a regular magnet, it's not a regular piece of iron. It's an unbelievably powerful magnet, and it's an unbelievably large piece of iron,' Kanal said, adding that the two factors resulted in 'hundreds of pounds of attraction in the direction of the magnet.' McAllister was pinned to the machine for over an hour by the massive exercise chain fitted with a padlock that he wore when he was allegedly led into the machine room by an MRI technician to help his wife who was having her knee examined, his family said. When he got 'within a few inches' of the machine, it could suddenly pull with 'such strength that it could have pulled sufficiently strongly to snap his neck,' Kanal said. 3 Family of McAllister claimed the 61-year-old was led into the machine room by a technician who did not tell the doting husband to remove his large metal chain. Brigitte Stelzer McAllister was pronounced dead at North Shore University Hospital the day after the bizarre accident with the cause being identified as three heart attacks, according to his family. '[D]epending on the status of his health, he may have had problems with cardiovascular disease before, and when the excitement happened, he could have had a heart attack just from the event itself,' Kanal stated. McAllister's wife described the haunting moments when her husband was breathing his last. 'His body went limp,' Adrienne Jones-McAllister told News 12 Long Island. 'He went limp in my arms and this is still pulsating in my brain,' she told the outlet through tears. Despite decades in the medical industry, Kanal said the bizarre manner of death is incredibly rare. 3 The MRI machine could have pulled McAllister with enough force to snap his neck, an expert told The Post. Brigitte Stelzer '[It's] extremely rare that someone dies because of an interaction with a strong magnetic field — probably fewer than a dozen times since MRI first became a diagnostic tool in the early 1980s,' the expert stated. His stepdaughter claimed the technician never warmed McAllister to take off the necklace that led to his demise. 'While my mother was laying on the table, the technician left the room to get her husband to help her off the table,' step-daughter Adrienne Jones-McAllister wrote in a GoFundMe. 'He forgot to inform him to take the chain he was wearing from around his neck off when the magnet sucked him in,' she wrote.
